Sino Biopharmaceutical’s Stock Price Dips to 3.60 HKD, Recording a 2.70% Loss: Is Now the Time to Buy?

Sino Biopharmaceutical (1177)

3.60 HKD -0.10 (-2.70%) Volume: 178.29M

Sino Biopharmaceutical’s stock price stands at 3.60 HKD, experiencing a -2.70% dip in the recent trading session with a trading volume of 178.29M. Despite the recent fluctuations, the stock maintains a positive year-to-date (YTD) performance of +12.50%, demonstrating its resilience in the market.

Latest developments on Sino Biopharmaceutical

Sino Biopharmaceutical (1177.HK) has been making significant strides in the pharmaceutical industry, recently announcing their ambitious target of launching 30 innovative products by 2027. The company’s stock price movements today were influenced by a series of key events, including the release of their strong financial results for 2024, which showed an annual net profit increase of 50.1% to RMB3.5 billion. Additionally, Sino Biopharmaceutical declared a final dividend for 2024 and reported a final dividend per share of HKD4 cents. These positive developments have garnered attention in the Asian market, positioning Sino Biopharmaceutical as a prominent player alongside other penny stocks in the industry.

Sino Biopharmaceutical on Smartkarma

Analysts on Smartkarma have differing views on Sino Biopharmaceutical. Xinyao (Criss) Wang suggests that the company’s acquisition of Hob Biotech may not bring much financial value or asset appreciation. The main purpose of the acquisition seems to be achieving an A-share listing, with limited synergies between the two companies. On the other hand, Janaghan Jeyakumar, CFA, provides insights on the HSCEI benchmark and capping flows, mentioning potential ADDs and DELs for the index rebal event in December 2024.

Xinyao (Criss) Wang‘s report questions the expensive purchase price of RMB33.74/share for Hob Biotech, considering its small market size and weak fundamentals. The future valuation of Hob will depend on the assets it receives from Sino Biopharm and its operational performance post-acquisition. Meanwhile, Janaghan Jeyakumar, CFA, focuses on the turnover estimate of US$474mn and potential changes in capping flows for the HSCEI benchmark. Investors following Sino Biopharmaceutical may find these insights valuable in their decision-making process.

A look at Sino Biopharmaceutical Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Based on the Smartkarma Smart Scores, Sino Biopharmaceutical Limited shows a promising long-term outlook. With above-average scores in resilience and momentum, the company demonstrates strong potential for growth and stability in the biopharmaceutical industry. While the scores for value, dividend, and growth are not as high, the overall outlook for Sino Biopharmaceutical appears to be positive, indicating a solid foundation for future success.

Sino Biopharmaceutical Limited, a company specializing in biopharmaceutical products for ophthalmia and hepatitis treatment, has received favorable ratings in resilience and momentum according to the Smartkarma Smart Scores. This suggests that the company is well-positioned to weather challenges and capitalize on opportunities in the market. While there is room for improvement in areas such as value, dividend, and growth, Sino Biopharmaceutical‘s overall outlook remains optimistic, reflecting its potential for continued growth and success in the long term.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma